Influence of GnRH analog therapy on body mass in central precocious puberty.

Głab E, Barg E, Wikiera B, Grabowski M, Noczyńska A

Pediatric endocrinology, diabetes, and metabolism1 Jan 2009Cited by 22 (Europe PMC)

PMID19454183PepBankPUB-19454183

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In girls with central precocious puberty, BMI SD score did not differ significantly between triptorelin initiation and treatment completion.
In plain wordsIn girls with central precocious puberty, BMI SD score did not differ significantly between triptorelin initiation and treatment completion.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBMI SD score
Study
n = 43
Comparator
Before treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg every 28 days · intramuscular · 3.3+/-2.2 yearAs given in this study (human).
Source sentences
Summary
There was no statistical difference between BMI SD score before initiation of therapy and at the end of therapy (p=0.49).
2 context sentences(design, population, supporting numbers)
Summary · context
43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days.
Summary · context
The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
Report a problemFND-1945418301
02HumanObservational studyEfficacy outcome
In girls treated with triptorelin, overweight prevalence changed from 9.8% to 18.6%, without a significant difference.
In plain wordsIn girls treated with triptorelin, overweight prevalence changed from 9.8% to 18.6%, without a significant difference.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOverweight prevalence
Study
n = 43
Comparator
Before treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg every 28 days · intramuscular · 3.3+/-2.2 yearAs given in this study (human).
Measurements
Overweight prevalence
9.8%
Before treatment
Overweight prevalence
18.6%
End of therapy
Source sentences
Summary
At the end of the therapy 18.6% children were overweight and 14.0% obese. These differences were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
9.8% of the cohort were overweight and 22.0% were obese before treatment.
Summary · context
43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days.
Summary · context
The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
Report a problemFND-1945418302
03HumanObservational studyEfficacy outcome
In girls treated with triptorelin, obesity prevalence changed from 22.0% to 14.0%, without a significant difference.
In plain wordsIn girls treated with triptorelin, obesity prevalence changed from 22.0% to 14.0%, without a significant difference.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeObesity prevalence
Study
n = 43
Comparator
Before treatment
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg every 28 days · intramuscular · 3.3+/-2.2 yearAs given in this study (human).
Measurements
Obesity prevalence
22%
Before treatment
Obesity prevalence
14%
End of therapy
Source sentences
Summary
At the end of the therapy 18.6% children were overweight and 14.0% obese. These differences were not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
9.8% of the cohort were overweight and 22.0% were obese before treatment.
Summary · context
43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days.
Summary · context
The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
Report a problemFND-1945418303

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In triptorelin-treated girls, final overweight and obesity showed no significant correlation with treatment duration.
In plain wordsIn triptorelin-treated girls, final overweight and obesity showed no significant correlation with treatment duration.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOverweight and obesity association with treatment duration
Study
n = 43
Outcome group
Body weight · Metabolic and weight
Measurements
Correlation (r) with duration of therapy
−0.17 r
Overweight and obesity at end of treatment
Source sentences
Summary
There was no significant correlation between overweight and obesity at the end of treatment and the duration of the therapy (r=-0.17) and with the duration of CPP before introduction of GnRH therapy (r= -0.11).
2 context sentences(design, population, supporting numbers)
Summary · context
43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days.
Summary · context
The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1945418304
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In triptorelin-treated girls, final overweight and obesity showed no significant correlation with CPP duration before treatment.
In plain wordsIn triptorelin-treated girls, final overweight and obesity showed no significant correlation with CPP duration before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOverweight and obesity association with pretreatment CPP duration
Study
n = 43
Outcome group
Body weight · Metabolic and weight
Measurements
Correlation (r) with CPP duration before GnRH therapy
−0.11 r
Overweight and obesity at end of treatment
Source sentences
Summary
There was no significant correlation between overweight and obesity at the end of treatment and the duration of the therapy (r=-0.17) and with the duration of CPP before introduction of GnRH therapy (r= -0.11).
2 context sentences(design, population, supporting numbers)
Summary · context
43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days.
Summary · context
The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1945418305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.